Kharagjitsingh A V, Dekker F W, Vandenbroucke J P
Leids Universitair Medisch Centrum, afd. Klinische Epidemiologie, Postbus 9600, 2300 RC Leiden.
Ned Tijdschr Geneeskd. 2004 Dec 18;148(51):2550-3.
A 73-year-old man, a 73-year-old woman, and a 57-year-old man with anaemia due to renal insufficiency were treated with epoetin. After 6-12 months, the haemoglobin level decreased despite dosage increases, after which the patients became dependent on regular transfusions of concentrated erythrocytes. The older man died from peritonitis following diagnostic examination because of the anaemia. The woman died from septic shock, even though epoetin had been replaced by darbepoetin. The haemoglobin level in the younger man returned to normal after the presence of antibodies against epoetin had been demonstrated, he had stopped using the drug, and he had started on immunosuppressive therapy following kidney transplantation. Since 1998, the number of patients with epoetin resistance due to the development of antibodies against the drug (epoetin-induced pure red-cell aplasia) has increased. This complication should be considered in every patient treated with epoetin who experiences unexplained transfusion-dependent anaemia.
一名73岁男性、一名73岁女性以及一名因肾功能不全导致贫血的57岁男性接受了促红细胞生成素治疗。6至12个月后,尽管增加了剂量,但血红蛋白水平仍下降,此后患者变得依赖定期输注浓缩红细胞。那名老年男性在因贫血进行诊断检查后死于腹膜炎。那名女性死于感染性休克,尽管促红细胞生成素已被达贝泊汀替代。在证实存在抗促红细胞生成素抗体、停用该药物并在肾移植后开始免疫抑制治疗后,较年轻男性的血红蛋白水平恢复正常。自1998年以来,因产生抗该药物抗体(促红细胞生成素诱导的纯红细胞再生障碍)而出现促红细胞生成素抵抗的患者数量有所增加。对于每一位接受促红细胞生成素治疗且出现无法解释的依赖输血性贫血的患者,都应考虑这种并发症。